Carisma Therapeutics Future Growth
Future criteria checks 0/6
Carisma Therapeutics's revenue and earnings are forecast to decline at 36.4% and 6.9% per annum respectively while EPS is expected to grow by 4% per annum.
Key information
-6.9%
Earnings growth rate
4.0%
EPS growth rate
Biotechs earnings growth | 34.0% |
Revenue growth rate | -36.4% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 09 Aug 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 10 | -74 | -43 | -41 | 2 |
12/31/2025 | 12 | -66 | -39 | -38 | 4 |
12/31/2024 | 23 | -56 | -69 | -69 | 3 |
6/30/2024 | 21 | -73 | -77 | -76 | N/A |
3/31/2024 | 15 | -81 | -79 | -78 | N/A |
12/31/2023 | 15 | -87 | -82 | -81 | N/A |
9/30/2023 | 14 | -83 | -83 | -82 | N/A |
6/30/2023 | 13 | -80 | -73 | -70 | N/A |
3/31/2023 | 12 | -75 | -69 | -65 | N/A |
12/31/2022 | 10 | -61 | -10 | -5 | N/A |
9/30/2022 | 6 | -57 | -2 | 3 | N/A |
6/30/2022 | 4 | -49 | -1 | 2 | N/A |
3/31/2022 | 1 | -43 | 4 | 7 | N/A |
12/31/2021 | N/A | -41 | -39 | -37 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: W2J is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: W2J is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: W2J is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: W2J's revenue is expected to decline over the next 3 years (-36.4% per year).
High Growth Revenue: W2J's revenue is forecast to decline over the next 3 years (-36.4% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if W2J's Return on Equity is forecast to be high in 3 years time